鍵凱科技(688356.SH):擬使用不超4.5億元閒置自有資金購買理財產品
格隆匯3月28日丨鍵凱科技(688356.SH)公佈,公司於2022年3月28日召開了第二屆董事會第十七次會議和第二屆監事會第十六次會議,審議通過了《關於公司使用閒置自有資金購買理財產品的議案》,為提高閒置自有資金的使用效率,同意公司使用額度不超過人民幣4.5億元的閒置自有資金購買風險較低、安全性高、流動性好、投資期限不超過12個月的理財產品(包括但不限於結構性存款、協定存款、通知存款、定期存款、大額存單、收益憑證和信託類產品),並在上述額度範圍內,資金滾動使用。上述事項有效期為自公司董事會審議通過之日起12個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.